Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status

• Conditions: PRIMARY FOCUS:PATIENT THAT TAKE CLOPIDOGREL

• Registration Number: NCT01210248
• Lead Sponsor: Assaf-Harofeh Medical Center

Brief Summary

The aim of this study is to check correlation between CYP2C19 genotype level of clopidogrel metabolite in plasma and platelet inhibition status.

Detailed Description

THE FIRST PHASE OF THE RESEARCH WILL INVOLVE PATIENTS RECRUITMENT AND INFORMED CONSENT FOR GENETIC TESTING.THE MAJORITY OF PATIENTS WILL BE RECRUITED FROM EMERGENCY DEPARTMENT. EVERY PATIENT WILL BE ASKED ABOUT HIS AND HIS PARENT'S ETHNICITY (ASHKENASI OR SEPHARDY JEW) AND ADDITIONAL DRUGS HE TAKES. IF PATIENT AGREES TO PARTICIPATE IN THE STUDY , HIS BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS:

1. GENETIC (FOR CYP450 2C19)

2. PLATELET MAPPING TEST ( BY THROMBOELASTOGRAPH ASSAY)

3. CLOPIDOGREL INACTIVE METABOLITE DETERMINATION BY CHROMATOGRAPHIC METHOD

Study Timeline

• Status Verified: 2010-05
• Study Start: 2010-09
• Study First Submitted: 2010-09-26
• Study First Submitted QC: 2010-09-27
• Last Update Submitted: 2010-09-27
• Study First Posted: 2010-09-28
• Last Update Posted: 2010-09-28
• Primary Completion: 2012-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• > 18 OLD PATIENTS
• THAT TAKE CLOPIDOGREL MORE THAN 1 WEEK

Exclusion Criteria

• PREGNANCY
• CHRONIC LIVER DISEASES

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Assaf Harofeh Medical Center; 🇮🇱 Zeriffin, Israel